P493 Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease
Notice bibliographique
Résumé
Infliximab have changed the natural history of inflammatory bowel diseases (IBD). However, with the advent of biosimilar treatment such as CT-P13 promises to improve availability of biological therapy. The annual risk of loss infliximab efficacy to be 13–15% per patient/year. The aim of the study is to compare the loss of efficacy of the treatment with Infliximab biosimilar (Remsima®) vs. original Infliximab (Remicade®) in patients with IBD who were “switched” from infliximab original (Remicade®). This was an observational ambispective cohort study of 1 year of follow-up. A cohort (retrospective) constituted by patients with IBD who had a treatment with original Infliximab (Remicade®) in the period of 2014–2015 and another cohort (prospective) constituted by patients whom were switched from infliximab reference (Remicade®) to CT-P13 treatment (Remsima®) in the period of 2015–2016. Baseline characteristics of the patients were analysed, as well as the loss of response in both periods after 12 months of treatment. The activity of the disease was evaluated at 0 and 12 months, according to the Harvey Bradshaw score and partial Mayo score for patients with CD and UC, respectively. The Baseline demographics and phenotypic characteristics of patients with CD and UC, according to the Montreal Classification, are shown in Table 1. Baseline demographics and phenotypic characteristics according to the Montreal classification. Prospective cohort, 98 patients with IBD were included (67 CD/31 CU), 56.1% men, 68.3% non-smokers. 83.6% (56 of 67) of the patients with CD were in remission at the time of the change and 67.7% (42 of 62) at 12 months. In patients with UC, 80.6% (25 of 31) were in remission at the time of the change and 69, 2% (18 of 26) at 12 months. In the retrospective cohort, 98 patients with IBD were included (67 CD/31 CU), 58.2% men, 68.3% non-smokers. 76.1% (51 of 67) of the patients with CD were in initial remission and 68.7% (46 of 67) at 12 months. In patients with UC, 83.9% (26 of 31) were in initial remission and 77.4% (24 of 31) at 12 months. When the loss of efficacy was compared in both periods, no statistically significant differences were observed (p > 0.5). Comparative results of the efficacy Remicade group vs. CT-P13. Both drugs have the same rate of loss of efficacy at 12 months. Therefore, the biosimilar of infliximab is as effective as the long-term reference drug. Comparative and prospective studies are needed to support these results.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».